Evaluation of [¹⁸F]-N-Methyl lansoprazole as a Tau PET Imaging Agent in First-in-Human Studies.

ABSTRACT: Development of positron emission tomography (PET) imaging agents capable of quantifying tau aggregates in neurodegenerative disorders such as Alzheimer's disease (AD) is of enormous importance in the field of dementia research. The aim of the present study was to conduct first-in-man imaging studies with the potential novel tau imaging agent [¹⁸F]N-methyl lansoprazole ([¹⁸F]NML). Herein we report validation of the synthesis of [¹⁸F]NML for clinical use by labeling the trifluoromethyl group via radiofluorination of the corresponding gem-difluoro enol ether precursor. This is the first use of this method for clinical production of PET radiotracers and confirmed that it can be readily implemented at multiple production facilities to provide [

SUBMITTER: Kramer V 

PROVIDER: S-EPMC7035908 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature